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Inﬂammatory pathways, meant to defend the organism against infection and injury, as a byproduct, can promote an environment
which favors tumor growth and metastasis. Tumor-associated macrophages (TAMs), which constitute a signiﬁcant part of the
tumor-inﬁltrating immune cells, have been linked to the growth, angiogenesis, and metastasis of a variety of cancers, most likely
through polarization of TAMs to the M2 (alternative) phenotype. The interaction between tumor cells and macrophages provides
opportunities for therapy. This paper will discuss secreted proteins as targets for intervention.
1.Introduction
Inﬂammatory pathways, meant to defend the organism
againstinfectionandinjury,asaby-product,canpromotean
environment which favors tumor growth and metastasis.
Severalinfections,inducinginﬂammation,havebeendirectly
linked to cancer. Well-known examples are Helicobacter
pyloriinfectionandgastriccancer[1],hepatitisBandCvirus
and hepatocellular carcinoma [2], and schistosomiasis and
bladder cancer [3]. Inﬂammation has therefore been coined
the seventh hallmark of cancer [4–7].
Macrophages are among the ﬁrst cells to inﬁltrate infect-
ed or damaged tissue [8]. Tumor-associated macrophages
(TAMs), which constitute a signiﬁcant part of the tumor-
inﬁltrating immune cells, have been linked to the growth,
angiogenesis, and metastasis of a variety of cancers, most
likely through polarization of TAM to the M2 (alterna-
tive) phenotype. M1 (classical) macrophages are generally
characterized by interleukin IL-12high,I L - 2 3 high,a n dI L -
10low phenotype. They produce reactive oxygen and nitrogen
intermediates as well as inﬂammatory cytokines and play
a role in Th1 responses. Finally, M1 macrophages mediate
resistance against intracellular parasites and tumors. M2
m a c r o p h a g e s( c h a r a c t e r i z e db ya nI L – 1 2 low,I L - 2 3 low,I L -
10high phenotype) are diverse, but in general are involved
in T helper 2 (Th2) response, have an immunoregulatory
function, and orchestrate encapsulation and containment
of parasites and promote tissue repair, remodeling, and
tumor progression. Further subdivision of M2 macrophages
into M2a (after exposure to IL-4 or IL-13), M2b (immune
complexes in combination with IL-1beta or LPS), and M2c
(IL-10, TGFbeta or glucocorticoids) has been suggested [9].
Whereas the vast majority of studies with numerous
tumor types, including follicular lymphoma [10], intestinal
type gastric cancer [11], pancreatic cancer [12], non-
gynecologic leiomyosarcoma [13], and thyroid cancer [14],
show that the presence of TAM in the tumor microenviron-
mentisassociatedwithaworseprognosis,somestudiesclaim
theopposite[15].ThespeciﬁcroleofTAMsincoloncanceris
more controversial, as most studies indicate that peritumoral
TAMs prevent tumor development (suggesting polarization
of TAMs towards the M1 phenotype); patients with high
TAM numbers have better prognosis and survival rate [16–
19]. In contrast, intratumoral TAM count has been corre-
lated with depth of invasion, lymph node metastasis, and
staging of CRC, suggesting that intratumoral macrophages
causecancercellstohaveamoreaggressivebehavior[20,21].
These contradictions may be due to diﬀerences in tumor
biology of diﬀerent tumor types, but may also be a conse-
quence of markers used for the study of TAM. Frequently,
the pan-macrophage/monocyte marker CD68 is used as a
marker for TAM, whereas the use of CD163 or CD204 might2 Clinical and Developmental Immunology
be more appropriate. In fact, Ohtaki et al. [22] show that
whereas presence of CD68+ macrophages was of marginal
prognostic signiﬁcance (P = 0.08) in lung adenocarcinoma,
the use of CD204 showed a strong association with poor
outcome in these patients (P = 0.007). Similarly, Espinosa
et al. found a very strong association between higher number
of CD163+ TAM and myometrial invasion of endometrioid
carcinoma. Furthermore, there was a positive correlation
between the number of CD163+ TAM in the primary
tumor and in regional lymph node metastases [23]. In
pancreatic cancer, high numbers of CD163- or CD204-
positive macrophages were associated with poor prognosis
(P = 0.0171); however, this was not the case for the number
of CD68-positive macrophages [12].
Finally, regardless of the marker used, it is frequently
reported that TAMs are associated with prognosis in univari-
ate analysis, but this association is lost in multivariate anal-
ysis [24–26]. An exception to this is Hodgkin’s lymphoma,
where an increased number of CD68+ macrophages out-
performed the international prognostic score in multivariate
analysis for disease-speciﬁc survival [27].
Nevertheless, it is clear that TAMs play an important
role in tumor growth and metastasis. This implies that
the interaction between tumor cells and TAM provides an
opportunity for cancer treatment. In this paper, we focus on
secreted proteins as targets for intervention.
2.SecretedProteins
2.1. CSF-1. The macrophage colony-stimulating factor
(CSF-1 or M-CSF) promotes the diﬀerentiation and survival
of macrophages. The receptor for CSF-1 is a tyrosine kinase
receptor encoded by c-fms. Both CSF-1 and the receptor are
expressed by tumor cells of diﬀerent origins [28, 29], and
elevated levels are associated with poor prognosis [30–33].
In fact, in epithelial ovarian cancer patients, elevated levels
of CSF-1 in serum or ascetic ﬂuid were associated with poor
outcome [34], whereas elevated levels after treatment were
indicators of recurrence of progression [35].
2.2. CCL2. Chemotactic cytokine ligand 2 (CCL2, also
known as monocyte chemoattractant protein 1 (MCP1),
monocyte chemotactic and activating factor (MCAF), and
monocyte secretory protein JE) is produced in a wide
range of tumors [36–39]. Expression of CCL2 is correlated
with TAM migration to the tumor, with high expression
resulting in higher numbers of TAM, as well as a higher
growth rate of tumors after in vivo transplantation [40].
Beside the eﬀect on monocytes, CCL2 has also been
shown to inhibit the generation of tumor-reactive T cells
[41]. Furthermore, prognostic analysis revealed that high
expression of CCL2 was a signiﬁcant indicator of early
relapse in human breast cancer patients [42], potentially
through the expression of angiogenic factors and activation
of matrix metalloproteinases [43]. These protumoral eﬀects
of CCL2 are in contrast with the ﬁndings of Zhang et
al. [44], who showed that early recruitment of monocytes,
by high-CCL2-producing tumors as opposed to low-CCL2-
producing tumors, inhibits tumor growth.
2.3. TNF. Whilst TNF-alpha was ﬁrst identiﬁed as a soluble
factor capable of inducing tumor necrosis [45], various
mechanisms have been described by which TNF-alpha may
promote cancer growth, invasion, and metastasis [46]. Two
receptors for TNF have been described, TNF-R1 and TNF-
R2. TNF-R1 is expressed on all cell types, whereas TNF-
R2 expression is limited to endothelial and immune cells
[47]. Mice deﬁcient in TNFR1 or TNFR2 were exposed to
chemicalstoinduceskintumorformation.Tumormultiplic-
ity was signiﬁcantly reduced in TNFR1−/− and TNFR2−/−
mice compared to wild-type mice, suggesting that both
r ec ept o rsha v ep r otumo racti vity .H o w ev e r ,TNFR1 −/−mice
were markedly more resistant to tumor development than
TNFR2−/− mice indicating that TNFR1 is the major media-
tor of TNF-alpha-induced tumor formation [48]. Constitu-
tive production of TNF from the tumor microenvironment is
a characteristic of many malignant tumors, and the presence
of TNF is often associated with poor prognosis. TNF has
been shown to induce tumor cell invasion through NF-
κB-andJNK-mediatedupregulationofmigration-inhibitory
factor in macrophages and through enhanced MMP pro-
d u c t i o ni nt u m o rc e l l s[ 49]. TNF further enhances cell
migration and metastasis through NF-κB-dependent induc-
tion of chemokines, interleukins, and intercellular adhesion
molecule-1 [49]. NF-κB, therefore, seems to play a key role
in a TNF-induced signaling pathway. NF-κBc a nb ea c t i v a t e d
by many stimuli, including proinﬂammatory cytokines (IL-
1, TNF), bacteria, LPS, viruses, and cellular stresses (UV,
radiation, chemotherapeutics) [50, 51]. Cellular targets of
NF-κB are cytokines, including TNF (positive feedback loop,
chemokines, adhesion molecules, inducible eﬀector enzymes
and regulators of apoptosis, and cell proliferation [51].
Hence, NF-κB plays a central role in inhibition of apoptosis
and tumor promotion and progression, suggesting that the
use of NF-κB inhibitors might be useful in cancer therapy.
Similarly, TNF inhibitors have been used for the treatment
of inﬂammatory and autoimmune diseases, but also for the
treatment of cancer. Several drugs are available, including
inﬂiximab, a human-mouse chimeric monoclonal antibody,
golimumab and adalimumab, fully human monoclonal
antibodies, certolizumab pegol, the PEGylated Fab fragment
of a humanized monoclonal antibody, and etanercept, a
fusion of the TNF receptor and an antibody constant region
(Fc). Inﬂiximab [52]a n de t a n e r c e p t[ 53]e s p e c i a l l ya r e
under study in clinical trials for the treatment of cancer.
However, treatment of rheumatoid arthritis and Crohn’s
disease with anti-TNF drugs, and especially the monoclonal
antibodies, was shown to be associated with an increased
risk of reactivation of tuberculosis [54]. Therefore, before
treatment with anti-TNF antibodies is initiated, a latent
tuberculosis infection should be ruled out. Furthermore, in
line with the important role of TNF in host defense and
tumor growth control, in patients with rheumatoid arthritis
treated with anti-TNF antibody therapy, the pooled odds
ratio for malignancy was 3.3 (95% conﬁdence interval, 1.2–
9.1) and for serious infection was 2.0 (95% conﬁdence
interval, 1.3–3.1) [55].Clinical and Developmental Immunology 3
2.4. IL-6. Secretion of IL-6 can be induced by exposure of
macrophages to LPS, and hence, can be seen as a representa-
tive product of the proinﬂammatory M1-type macrophages.
On the other hand, IL-6 promotes cancer cell proliferation
while also inhibits apoptosis of cancer cells through acti-
vation of signal transducer and activator of transcription 3
(Stat3) [56]. Stat3 is activated by phosphorylation on Tyr-
705, which leads to dimer formation, nuclear translocation,
and regulation of gene expression. Serine phosphorylation
of Stat3, induced by IL-6 stimulation, has been shown to
be independent of mitogen-activated protein kinase and
sensitive to the Ser/Thr kinase inhibitor H7. PKC delta is
likely to be the kinase that phosphorylates Stat3 in response
to IL-6 [57, 58]. Additionally, IL-6 acts as an angiogenic
factorandhasbeenimplicatedinmanyofthesameprocesses
as TNF. Notably, during the cross-talk between cancer
and inﬂammatory cells, Stat3 and NF-κBs e e mt ob ek e y
transcription factors linking a mutual positive feedback loop
and promoting cancer progression [56] .At i s s u em i c r o a r r a y
study on 221 ovarian cancer cases showed that the intensity
of IL-6 staining correlated with prognosis [59]. These data
provide the rationale for the use of anti-IL-6 antibodies
and STAT-3 inhibitors. A number of clinical studies using
siltuximab (CNTO 328), a chimaeric anti-IL-6 monoclonal
antibody, have been reported [60–63]. Furthermore, a
high-aﬃnity fully humanized anti-interleukin 6 monoclonal
antibody (mAb 1339) is available and has shown in vitro
and in vivo antimultiple myeloma activity, both alone and
in combination with conventional and novel agents against
multiple myeloma [64]. Similarly, sirukumab (CNTO 136), a
human monoclonal antibody against soluble IL-6, has been
investigated in healthy subjects, showing that it is safe and
has a low immunogenicity [65]. Finally, a range of STAT3
inhibitorshavebeentestedandshowntohavestronggrowth-
inhibitory activity against cancercell lines invitro and potent
antitumor eﬀects in vivo (as reviewed by [66]). Currently,
two clinical trials are ongoing, evaluating blockade of STAT3
in solid tumors (NCT00696176, phase 0, and NCT00955812,
phase 1), but no results are currently available.
2.5. CCL5. Chemokine (C-C motif) ligand 5 (CCL5),
also known as regulated upon activation, normal T-cell
expressed, and Secreted (RANTES), plays an important
role in T-cell proliferation and IFN-γ and IL-2 production,
which promotes the diﬀerentiation and proliferation of Th1
cells important for immune defense against intracellular
infection. It was shown that the prostaglandin E2, secreted
by mammary gland tumor cells, but not by normal mam-
mary gland epithelial cells, inhibited CCL5 expression in
macrophages in response to LPS, but not to TNF-α stim-
ulation [67]. Furthermore, an inverse correlation between
tumoral CCL5 expression and number of macrophages in
the tumor microenvironment has been reported [68], which
suggests an antitumoral, rather than a protumoral, role of
CCL5. However, when an antagonist of the CCL-5 receptors,
CCR1 and CCR5, was used in a mouse model of breast
cancer, a signiﬁcant reduction in volume and weight of
treated animals versus controls was observed. The antagonist
also showed activity against established tumors [69].
2.6. CCL18. Chemokine (C-C motif) ligand 18 (CCL18) is
a small cytokine belonging to the CC chemokine family.
It was identiﬁed, more or less simultaneously, from a
range of sources, leading to diﬀerent names: found highly
expressed in lung, it was called pulmonary and activation-
regulated chemokine [70] (PARC); based on its similarity
to CCL3 it was called macrophage inﬂammatory protein-
4[ 71] (MIP-4); after being cloned from dendritic cells, it
was called dendritic cell-chemokine 1, [72]( DC - C K 1 ) ;wh e n
macrophages were the source for cloning, it was called alter-
native macrophage activation-associated CC chemokine-1
[73] (AMAC-1).
CCL18 is predominantly produced by monocytes/
macrophages and dendritic cells (DCs). In case of macro-
phages, expression of CCL18 can be induced both by Th1
signals (i.e., LPS) and by Th2 signals (i.e., IL-4, IL-10,
and IL-13). Immunohistochemistry has shown that CCL18
is produced by CD163+ macrophages [74–76]. Immature
DCs express high levels of CCL18, but there is controversy
on the eﬀect of maturation, with some reports claiming
upregulation[77–79]andothersclaimingdownregulationof
CCL18 expression [73, 80, 81]. CCL18 is likely to participate
in homing of lymphocytes and DC to secondary lymphoid
organs. In case of serious inﬂammation, CCL18 could assist
in mounting a primary immune response through the
attraction of na¨ ıve T cells towards fully matured DCs [82,
83].However,intheabsenceofcostimulatorymolecules,this
canleadtotheinduction oftolerancethroughthegeneration
of regulatory T cells (Tregs [84–86]). Furthermore, it has
recently been shown that CCL18 can convert memory T-
cells to Tregs [87]. Tregs, in turn, can upon coculture induce
macrophages to display typical features of alternatively
activated macrophages such as CD163 and CD206 and
increased production of CCL18 [88], providing a positive
feedback loop. Finally, as a CCR3 antagonist [89], CCL18
may limit the recruitment of eosinophils and basophils and
hence dampen a local pro-allergic reaction [89, 90]. These
data on the role of CCL18 under normal physiological
conditions gave an indication that CCL18 might play a role
in tumor development. This was underscored by the ﬁnding
of high levels of expression of CCL18 by tumor-associated
macrophages in glioma and ovarian and gastric cancer [91–
94]. Furthermore, it was shown that the serum level of
CCL18 was elevated in epithelial ovarian cancer patients. In
fact, in a study of 51 patients with epithelial ovarian cancer,
27 patients with benign ovarian lesions and 29 healthy
volunteers, serum CCL18 gave a sensitivity of 84.3% and a
speciﬁcity of 91.1% [94]. As Duluc et al. [95] showed that
IFN gamma was able to switch immunosuppressive TAM
intoimmunostimulatory cells,withaconcomitantreduction
in CCL18 secretion, this may be a potential route for therapy.
Recently, PITPNM3 was identiﬁed as the functional
receptor for CCL18 that mediates CCL18 eﬀect and activates
intracellular calcium signaling. This receptor is the mam-
malian homologue for Drosophila melanogaster rdgB, which
is an essential protein for photoreceptor-cell survival and
light response [96]. However, the protein appears to be also
involved in regulation of cytoskeletal elements [96], which
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shown that suppression of PITPNM3 abrogated the eﬀect
of CCL18 on the invasion and metastasis of breast cancer
xenografts [97]. This receptor might therefore be a potential
target for therapy.
On the other hand, a tumor-suppressive function of
CCL18 cannot be entirely ruled out as Leung et al. [92]
reported that in gastric cancer, CCL18 was expressed by
a subset of tumor-associated macrophages, located at the
tumor invasion front and that high CCL18 expression levels
were associated with prolonged overall and disease-free
survival.
2.7. MMPs. Matrix metalloproteinases (MMPs) are zinc-
dependent endopeptidases, which function to degrade all
kinds of extracellular matrix proteins. The MMPs have
been shown to play important roles in tissue remodeling
associated with various physiological and pathological pro-
cesses such as morphogenesis, angiogenesis, tissue repair,
cirrhosis, arthritis, and metastasis. MMP-2 and MMP-9
especially are thought to be important in preparing the
way for tumor cells to metastasize. In contrast, MMP-12
seems to have an antitumoral activity, in that it both retards
tumor growth and suppresses growth of lung metastases
[98]. Similarly, MMP-3 is thought to be expressed as a
protective response and may play a role in host defense
during tumorigenesis [99], although MMP3 has also been
associated to vascular invasion by immunohistochemistry
[100]. Furthermore, MMP-3 regulates macrophage secretion
ofprostaglandinE2andexpressionofMMP-9[101].Speciﬁc
endogenous tissue inhibitors of metalloproteinases (TIMPs)
act to inhibit MMPs. These TIMPs comprise a family of four
protease inhibitors: TIMP1, TIMP2, TIMP3, and TIMP4.
It has been shown that in renal cell carcinoma the balance
between MMP and TIMP is disturbed, possibly due to the
production of radical oxygen species by TAM [102].
3. Treatment
3.1. Blocking the Diﬀerentiation and Recruitment of Ma-
crophages. Although the association between CSF-1 and
enhanced tumorigenesis is evident, CSF-1 also plays an
important role in lactation, ovulation, preimplantation,
and placental function [103, 104], restricting its role as
therapeutic target. The expression of c-fms in normal
tissue, on the other hand, is limited to macrophages,
except during pregnancy [105], making it a better tar-
get for therapy, although indiscriminate destruction of
macrophages can have serious consequences for health,
including decreased liver function and vulnerability to
infectious diseases. Nevertheless, a number of agents have
been developed to speciﬁcally target c-fms, as well as some
multitargeted agents, showing c-fms inhibition in enzyme
and cell-based assays [106]. Currently, three phase 1 clinical
trials involving c-fms inhibitors are recruiting patients
(NCT01004861, NCT01316822, and NCT01346358) (clini-
caltrials.gov, accessed 2011/08/26). These studies will show
whether c-fms inhibitors are of value in cancer therapy or
result in unacceptable levels of toxicity.
The minor groove binding agent Yondelis was used to
investigate the immunomodulatory eﬀects on leukocytes.
At subcytotoxic concentrations, Yondelis inhibited the dif-
ferentiation of monocytes to macrophages. The production
of CCL2 and IL6 by monocytes, macrophages, TAMs, and
tumor cells was also markedly reduced [107]. In the case of
human myxoid liposarcoma, in vitro treatment of primary
tumor cultures and/or cell lines with noncytotoxic concen-
trations of Yondelis selectively inhibited the production of
CCL2, IL-6, and VEGF. A xenograft mouse model of human
MLS showed marked reduction of CCL2, CD68+-inﬁltrating
macrophages, and CD31+ tumor vessels after treatment with
Yondelis. Similar ﬁndings were observed in a patient tumor
sample excised after several cycles of therapy [108].
After subcutaneous injection of prostate cancer cells in
male SCID mice, systemic administration of anti-CCL2 anti-
bodies signiﬁcantly retarded tumor growth and attenuated
macrophage inﬁltration, with a concomitant decrease in
microvascular density [109]. Treatment of immunodeﬁcient
mice bearing human breast cancer cells with a neutralizing
antibody to CCL2 resulted in a signiﬁcant decrease of
macrophage inﬁltration, angiogenic activity, and tumor
growth [68]. Similarly, CCL2 blockade by antimurine CCL2
monoclonal antibodies signiﬁcantly slowed the growth of
primary tumors and inhibited lung metastasis in animal
models of non-small-cell lung cancer. The treatment did not
have eﬀect on the number of TAM, but seemed to elicit
a change of TAM to a more antitumor phenotype [110].
To investigate another route to block CCL2, a dominant
negative CCL2 mutant gene was transfected in the thigh
muscleinamodelofhumanmelanomacellsbeingimplanted
onto the back of a mouse. The dominant negative CCL2
inhibited TAM recruitment and partially reduced tumor
angiogenesis and tumor growth [111].
CNTO 888, a human mAb speciﬁc for human CCL-
2, is under current investigation in two clinical trials, one
as single agent in patients with metastatic prostate cancer
(NCT00992186) and the other in combination with stan-
dard of care chemotherapy in patients with solid tumors
(NCT01204996). Furthermore, MLN1202, a highly speciﬁc
humanized monoclonal antibody that interacts with CCR2
and inhibits CCL-2 binding, is being used in a phase II
trial in patients with bone metastases (NCT01015560). In
a related study on MLN1202 treatment in patients at risk
of atherosclerotic cardiovascular disease, patients were geno-
typed for the 2518 A→G polymorphism in the promoter
of the MCP-1 gene. Patients with A/G or G/G genotypes in
the MCP-1 promoter had signiﬁcantly greater reductions in
high-sensitivity C-reactive protein levels than patients with
the wild-type A/A genotype [112]. This polymorphism may
also aﬀect the outcome in studies of cancer patients.
Following the initial report on cyclooxygenase-2 (COX-
2) overexpression in colorectal cancer [113], COX-2 has
been the focus of attention as a potential target for cancer
treatment. In contrast with COX-1, which is constitutively
expressed, COX-2 expression levels are low or undetectable
in normal tissues under basal conditions, with the exception
oftheseminalvesicles,kidneys,andcertainareasofthebrain,
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[114]. However, COX-2 overexpression has been found in
a wide range of solid and hematological tumors (reviewed
in [115]). Clinical and epidemiological investigations as well
as experimental studies have shown that COX-2 contributes
to tumourigenesis in every stage: tumor initiation, tumor
promotion, and tumor spread. One of the mechanisms
involved is the creation of an inﬂammatory environment.
As discussed in Section 1, chronic inﬂammation constitutes
a risk factor for carcinogenesis. Prostaglandin E2 (PGE2)
is the most abundant among the prostaglandins produced
by COX-2-expressing tumors [116]. The release of PGE2
provides a positive feedback loop [117], which ensures
lasting levels of COX-2 in the tumor environment. A role of
PGE2-dependent signaling pathways has been described in
tumor growth, angiogenesis, tumor invasion and metastasis,
tumor survival, and tumor immune tolerance (reviewed
in [115]). Given the importance of COX-2 and PGE2, a
range of COX-2 inhibitors have been developed. These
compounds showed encouraging results in vitro and in vivo
[118, 119] and were introduced in clinical trials for both
chemoprevention as well as cancer therapy. Three large
randomized clinical trials conﬁrmed the eﬃcacy of COX-2
inhibitors for chemoprevention [120–122], however, at the
cost of a signiﬁcant increase in incidence and severity of
thrombotic events [123]. This increased risk, however, could
not be conﬁrmed in a meta-analysis of 72 studies, unless
patients had previous risk factors for cardiovascular disease
[124].
More speciﬁcally, towards a potential association be-
tween COX-2 and TAM, the COX inhibitor DFU (5,5-
dimethyl-3-(3-ﬂuorophenyl)-4-(4-methylsulphonyl)phenyl-
2(5H)-furanone) was investigated in a rat tumor model and
signiﬁcantly reduced the CCL2 production, as measured
both in tumor tissue and in the systemic circulation, with
concomitant reduction of the tumor size [125]. Despite
these, and other encouraging preclinical results, results of
large randomized trials, comparing chemotherapy alone
or in combination with COX inhibitors, have been less
promising so far [126, 127].
3.2. Killing of Macrophages in the Tumor Microenviron-
ment. Bisphosphonates are known to kill macrophages. In
a study by Gazzaniga et al., clonodrate-loaded liposomes
(CLIPs) were administered to melanoma-bearing mice. The
macrophage depletion following this treatment resulted in
smaller tumors, with fewer vascular structures [128]. Sim-
ilarly, in an orthotopic, immunocompetent murine model
of diﬀuse malignant peritoneal mesothelioma, intraperi-
toneal injection of CLIP leads to apoptosis in tumor
cells. Furthermore, when CLIP was injected together with
mesothelioma cells, there were a 4-fold reduction in number
of tumors and a 5-fold reduction in invasion and metastasis,
compared to liposome-encapsulated PBS. Even in mice
bearing established tumors, i.p. injected CLIP resulted in
a signiﬁcant reduction in number of tumors [129]. In a
study investigating the use of CLIP in several types of tumor
in mice, Takahashi et al. showed that injection of CLIP in
four spots around the tumor on day 0 or 5 after tumor
injection and every third day thereafter resulted in tumor
rejection after 12 injections. Depletion of macrophages by
CLIP injection before radiotherapy increased the antitumor
eﬀect of ionizing radiation [130]. The combination of
CLIP with the small molecule sorafenib, for the treatment
of a mouse metastatic liver cancer model, was shown to
inhibit tumor progression, tumor angiogenesis, and the
development of lung metastasis signiﬁcantly better than
sorafenib alone [131]. In this study, zoledronic acid, another
bisphosphonate, was shown to be even more eﬀective than
clodronate [131]. In an in vitro model of prostate cancer
cell-macrophage interaction, zoledronic acid selectively sup-
pressed the expression of MMP-9 by TAM, whereas the
expression of other mediators was not lowered. Zoledronic
acid also boosted the production of type-1 cytokines by
PC-TAM in response to immunomodulators such as IL-
12, which is known to polarize macrophages towards an
antitumoral M1 phenotype [132]. In conclusion, depletion
of macrophages in and around the tumor has been shown
to give encouraging results in mouse models, most likely
by taking out the paracrine signaling by TAM to tumor
cells. However, in most cases, bisphosphonates were given
simultaneously with the challenge with tumor cells, which
obviously is not the situation in patients. Nevertheless,
bisphosphonates have been used extensively in humans,
while it becomes apparent that their usage is not without
risk. The most common adverse eﬀects associated with
the use of bisphosphonates are renal toxicity, acute-phase
reactions, gastrointestinal toxicity, and osteonecrosis of the
jaw. The incidence of these adverse events varies signiﬁcantly
among bisphosphonates. Renal toxicity is a potentially life-
threatening event reported in studies of zoledronic acid and,
to a lesser extent, pamidronate. In contrast, the renal safety
proﬁle of intravenous ibandronate and oral bisphosphonates
issimilartothatofplacebo.Acute-phasereactionsoccuronly
with intravenous aminobisphosphonates and may be more
common with zoledronic acid. Gastrointestinal eﬀects occur
only with oral agents (clodronate and ibandronate) [133].
Careful monitoring of patients, not only for the adverse
events described above, but also for infectious diseases
and liver failure, due to the indiscriminate destruction of
all phagocytic myeloid cells by bisphosphonates, is strictly
necessary.
3.3. Repolarization of TAMs. Administration of the proton
pump inhibitor pantoprazole to mice with T-cell lymphoma
resulted in enhanced TAM recruitment to the tumor envi-
ronment. These TAMs had the M1 phenotype. Pantoprazole
leads to a reversal of immunosuppression and a shift in the
cytokine proﬁle [134]. The antitumor eﬀect of pantoprazole
was evaluated in vivo by a xenograft model of nude mice.
After pantoprazole treatment, apoptotic cell death was
seen selectively in cancer cells. By contrast, normal gastric
mucosal cells showed resistance to pantoprazole-induced
apoptosis through the overexpression of antiapoptotic reg-
ulators including HSP70 and HSP27 [135]. A phase I study
evaluating pantoprazole in combination with doxorubicin6 Clinical and Developmental Immunology
for advanced cancer patients is currently recruiting patients
(NCT01163903).
IL12, which promotes tumoricidal responses and is nor-
mally produced by M1 macrophages, induces tumor regres-
sion when used in tumor-bearing mice [136].This treatment
induced a reduction of M2-associated chemokines and an
increase in M1-associated chemokines [136]. Further study
by this group revealed that the rapid release of IL-15 after
IL-12 treatment is essential for inﬁltration of the tumor
and surrounding tissue by leukocytes, including CD8+ T
cells, substantiating the repolarization by IL-12 to M1 [137].
In a study by Airoldi et al., the IL-12 receptor beta2
unit was introduced into Calu6 cells by transfection. IL-
12 treatment of transfected Calu6/beta2(+) cells inhibited
angiogenesisinvitro.T umorsinSCID/NODmice,formedby
cells transfected with IL-12Rbeta2, were signiﬁcantly smaller
following IL-12 versus PBS treatment due to inhibition of
angiogenesis and of IL-6 and VEGF-C production [138].
Application of repeated doses of IL-12 to cancer patients
resulted in a Th1 to Th2 shift (increase in IL10, decrease in
IFN-gamma, TNF-alpha, and IP10 in serum of the patients)
[139, 140]. This may indicate a potential limitation of the
use of IL-12 as a single agent, which is underscored by the
ﬁnding of a limited eﬃcacy in most clinical trials with IL-
12 [141]. However, combined administration of IL-12 with
other cytokines, such as IL-2, IL-15, IL-7, IL-21, IL-18, GM-
CSF, or IFN-alpha, seems to overcome this problem [142].
Furthermore, when coadministered, a lower eﬀective dose
of IL-12 is necessary, reducing potential toxicity, as high
toxicity is another limitation of IL-12 therapy [143]. Finally,
local administration of the cytokine(s), rather than systemic
administration, also reduces the problem of toxicity [142].
For polarization of macrophages towards the alternative
phenotype (M2), NF-κbn e e d st ob ea c t i v e .W h e nN F - κb
signaling is inhibited, the macrophages become cytotoxic
to tumor cells, resulting in vivo in regression of advanced
tumors [144]. Inhibition of NF-κb signaling may therefore
be an alternative for IL-12 administration.
The host-produced histidine-rich glycoprotein (HRG)
was shown to inhibit tumor growth and metastasis while
improving sensitivity to chemotherapy. This was accom-
plished by skewing TAM polarization from M2 to M1 phe-
notype, accompanied by a promotion of antitumor immune
responsesandvesselnormalization,throughdownregulation
of the placental growth factor [145]. The RCAS/TV-A mouse
model for gliomas was used to investigate the eﬀect of
HRG on brain tumor development. Tumors were induced
with platelet-derived growth factor-B (PDGF-B), in the
presence or absence of HRG. HRG was found to have little
eﬀect on tumor incidence but could signiﬁcantly inhibit the
development of malignant glioma and completely prevent
the occurrence of glioblastoma [146].
3.4. Inhibition of M2 Macrophage Functions. Prednisolone
has been used to investigate its eﬀect on TAM melanoma-
bearing mice. The major inhibitory action on tumor growth
was the reduction of TAM-mediated production of proan-
giogenic factors, whereas the production of antiangiogenic
factors was hardly aﬀected [147]. Liposomes encapsulating
prednisolone phosphate were developed to evaluate the
local delivery of liposomal glucocorticoids to the tumor
and its importance for the therapeutic response. A single
dose of prednisolone liposomes was found to signiﬁcantly
inhibit tumor growth in mice, subcutaneously inoculated
with B16F10 melanoma cells. Uptake of liposomes by TAM
was limited to only 5% of the TAM population, and the
therapydidnotleadtoTAMdepletion.However,a90%drop
in white blood cell count after prednisolone administration
was observed. This depletion may reduce tumor inﬁltration
of monocytes, which stimulate angiogenesis, and possibly
cocontributes to the antitumor eﬀects [148].
Silibinin has demonstrated anticancer eﬀects against,
amongstothers,humanprostateadenocarcinomacells[149],
human ovarian cancer [150], human colon cancer cells
[151], and human lung carcinoma cells [152]. Oral silibinin
was tested on established lung adenocarcinomas in A/J mice.
Silibinin strongly decreased tumor number and size, prob-
ably by an antiangiogenic mechanism [153]. One clinical
study using silibinin in advanced hepatocellular carcinoma
is ongoing (NCT01129570), and another study in men with
prostate cancer has been completed [154, 155]. This study
showed that high-dose oral silybin-phytosome achieved high
blood concentrations transiently, but only low levels of
silibinin were seen in prostate tissue. Furthermore, one of
the six treated patients developed a grade 4 postoperative
thromboembolic event [155].
In the FL-2000 trial, patients with follicular lymphoma
were randomly assigned to receive standard treatment
(cyclophosphamide, doxorubicin, etoposide, prednisolone,
and interferon) or standard treatment plus rituximab. This
chimeric monoclonal antibody binds to CD20, which is
widely expressed on B cells, from early pre-B cells to later in
diﬀerentiation. In the control arm, a low number of TAM
(CD68+) was associated with a better event-free survival,
whereas this eﬀect was not observed in the rituximab arm,
which suggests that rituximab is able to circumvent the
unfavorable outcome associated with a high number of
TAM [156]. In fact, after rituximab and cyclophosphamide-
doxorubicin-etoposide-prednisone regimen, high TAM con-
tent correlated with longer survival rates. In multivariate
analyses, TAM content remained an independent prognostic
f a c t o rf o rO Sa n dP F S[ 157]. It was recently shown that,
in vitro, Ms4a8a mRNA and MS4A8A protein (a CD20
homologue) expression was strongly induced in bone-
marrow-derived macrophages by combining M2 mediators
(IL-4, glucocorticoids) and tumor-conditioned media [158].
If this CD20 homologue is also expressed on TAM, this could
explain the activity of rituximab.
4. Conclusions
Itisclearthatthereareseveralinstantsofinteractionbetween
tumorcellsandmacrophageswheretherapeuticintervention
is a possibility. On the other hand, early stages of interaction,
such as diﬀerentiation and chemotaxis, may already have
occurred at the time of diagnosis. Whereas in mouse
models c-fms inhibitors, anti-CCL2 monoclonal antibodies,
or bisphosphonates can be given before, or simultaneously,Clinical and Developmental Immunology 7
with inoculation with tumor cells, in humans this is not the
case.Limitedevidenceisavailabletosupportposthoceﬃcacy
of these kinds of treatment.
Perhaps the most interesting intervention would be the
repolarization of macrophages, as this will turn the ally into
an enemy, ﬁghting the cancer at close range. From the agents
described to invoke repolarization, IL-12 might be the most
interesting candidate, with66clinicaltrialsindiﬀerentstages
of execution. While not designed to investigate the eﬀect of
IL-12 on the interaction between tumor and TAM, these
studies may reveal positive eﬀects that will pave the way
for new studies investigating the eﬀect of IL-12 on TAM,
speciﬁcally.
Regardless of the route chosen to block interaction
between tumor cells and macrophages, it has become clear
that whereas a reduction in tumor growth, angiogenesis, and
metastasis can be obtained, complete clearance of the tumor
is unlikely. Therefore, combination with chemo- and/or
radiotherapy will remain essential.
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